# Chemomab Therapeutics Ltd. > Alpha governed public record. Unknown, unavailable, and unpublished values are never inferred as zero. ## Record | Field | Value | | --- | --- | | Representation | alpha-profile-markdown-v4 | | Protocol | Alpha Governance Facts Protocol 0.1 | | Schema | alpha.governance.entity.public.v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | Governance record representation | alpha-governance-record-v2 | | Canonical entity | alpha:company:b1855362-5134-4427-ae32-49edcf67e58e | | Entity type | Company | | Canonical URL | https://registry.alpha.ac/companies/chemomab-therapeutics-ltd | | Publication | PUBLISHED | | Verification | source_reported | | Verification schema | alpha-verification-states-v1 | | Ownership | unclaimed | | Published claims | 25 | | Claims under review | 1 | | Evidence records | 7 | | Conflicts | 0 | | Conflicts in internal review | 0 | | Observed | 2026-10-17T04:47:19.235235+00:00 | | Last reviewed | 2026-10-17T04:47:19.235235+00:00 | ## Identity - Legal name: Chemomab Therapeutics Ltd. - Display name: Chemomab Therapeutics Ltd. ## Alpha Governance Record | Field | Value | | --- | --- | | Governance Record schema | alpha-governance-record-v2 | | Ontology | alpha-governance-ontology-v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | As of | 2026-10-17T18:19:41.498462+00:00 | | Completeness | 0.409 | | Record Quality | 0.84 | | Directors | 7 | | Committees | 6 | | Governance events | 18 | | Entity class | public_company | ## Section coverage | Section | State | | --- | --- | | identity | PUBLISHED | | corporate_structure | NOT_REVIEWED | | board | PUBLISHED | | committees | PUBLISHED | | leadership | PUBLISHED | | ownership | NOT_REVIEWED | | financials | NOT_REVIEWED | | capital_structure | PUBLISHED | | compensation | NOT_REVIEWED | | governance | NOT_REVIEWED | | shareholder_governance | NOT_REVIEWED | | audit | NOT_REVIEWED | | legal | NOT_REVIEWED | | risk | NOT_REVIEWED | | cyber | NOT_REVIEWED | | ai_governance | NOT_REVIEWED | | agent_governance | RESTRICTED | | markets_external | NOT_REVIEWED | | events | PUBLISHED | | relationships | PUBLISHED | | assessments | PUBLISHED | | evidence | PUBLISHED | ## Board - Adi Mor: Director. Status: current. Independent: false. Since: 2021-01-01. claim_id=alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:5 - Alan Moses: Director. Status: current. Independent: true. Since: 2021-01-01. Committees: Audit (member). claim_id=alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:6 - Claude Nicaise: Director. Status: current. Independent: true. Since: 2021-01-01. Committees: Audit (member). claim_id=alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:7 - Dale Pfost: Director. Status: current. Independent: false. Since: 2021-01-01. claim_id=alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:8 - Joel Maryles: Director. Status: current. Independent: true. Since: 2021-01-01. Committees: Audit (chair); Audit · Chair; Nominating and Governance (member); Nominating and Governance (member). claim_id=alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:9 - Neil Cohen: Director. Status: current. Independent: true. Since: 2020-01-01. Committees: Compensation (member); Compensation; Nominating and Governance · Chair (member); Nominating and Governance (chair). claim_id=alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:10 - Nissim Darvish: Director. Status: current. Independent: true. Since: 2021-01-01. Committees: Compensation (chair); Compensation · Chair (member). claim_id=alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:11 ## Committees - Audit (audit). Chair: Joel Maryles. Members: Joel Maryles (chair, current); Alan Moses (member, current); Claude Nicaise (member, current). committee_id=alpha:committee:chemomab-therapeutics-ltd:audit - Audit · Chair; Nominating and Governance (audit). Chair: NOT_PUBLISHED. Members: Joel Maryles (member, current). committee_id=alpha:committee:chemomab-therapeutics-ltd:audit-chair-nominating-and-governance - Compensation (compensation). Chair: Nissim Darvish. Members: Nissim Darvish (chair, current); Neil Cohen (member, current). committee_id=alpha:committee:chemomab-therapeutics-ltd:compensation - Compensation · Chair (compensation). Chair: NOT_PUBLISHED. Members: Nissim Darvish (member, current). committee_id=alpha:committee:chemomab-therapeutics-ltd:compensation-chair - Compensation; Nominating and Governance · Chair (compensation). Chair: NOT_PUBLISHED. Members: Neil Cohen (member, current). committee_id=alpha:committee:chemomab-therapeutics-ltd:compensation-nominating-and-governance-chair - Nominating and Governance (nominating_governance). Chair: Neil Cohen. Members: Neil Cohen (chair, current); Joel Maryles (member, current). committee_id=alpha:committee:chemomab-therapeutics-ltd:nominating-and-governance ## Executive leadership - Adi Mor: Director, Chief Scientific Officer. Status: current. claim_id=alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:12 - Dale Pfost: Chairman of the Board, Chief Executive Officer [CEO]. Status: current. claim_id=alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:13 - Donald Marvin: Chief Financial Officer, Executive Vice President and Chief Operating Officer [CFO]. Status: current. claim_id=alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:14 - Matthew Frankel: Chief Medical Officer. Status: current. claim_id=alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:15 ## Governance events - EXECUTIVE_APPOINTED: Adi Mor executive of Chemomab Therapeutics Ltd., effective 2023-03-20. Effective: 2023-03-20. Detected: 2026-10-17T04:47:19.235235+00:00. event_id=alpha:event:transition:1l6zvvq1q14xju - CEO_CHANGED: Dale Pfost executive of Chemomab Therapeutics Ltd., effective 2023-03-20. Effective: 2023-03-20. Detected: 2026-10-17T04:47:19.235235+00:00. event_id=alpha:event:transition:olmm381cdyb7i - CFO_CHANGED: Donald Marvin executive of Chemomab Therapeutics Ltd., effective 2023-03-20. Effective: 2023-03-20. Detected: 2026-10-17T04:47:19.235235+00:00. event_id=alpha:event:transition:irccnt131o0lt - EXECUTIVE_APPOINTED: Matthew Frankel executive of Chemomab Therapeutics Ltd., effective 2023-03-20. Effective: 2023-03-20. Detected: 2026-10-17T04:47:19.235235+00:00. event_id=alpha:event:transition:z7r33r4gdzsv - DIRECTOR_APPOINTED: Adi Mor seat on Chemomab Therapeutics Ltd., effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-17T04:47:19.235235+00:00. event_id=alpha:event:transition:p7h3a6u8o8bu - DIRECTOR_APPOINTED: Alan Moses seat on Chemomab Therapeutics Ltd., effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-17T04:47:19.235235+00:00. event_id=alpha:event:transition:188d5vv1m19snh - DIRECTOR_APPOINTED: Claude Nicaise seat on Chemomab Therapeutics Ltd., effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-17T04:47:19.235235+00:00. event_id=alpha:event:transition:7os8kcqhkq8 - DIRECTOR_APPOINTED: Dale Pfost seat on Chemomab Therapeutics Ltd., effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-17T04:47:19.235235+00:00. event_id=alpha:event:transition:blsrspl7f4a3 - DIRECTOR_APPOINTED: Joel Maryles seat on Chemomab Therapeutics Ltd., effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-17T04:47:19.235235+00:00. event_id=alpha:event:transition:wjlaom1eyqspi - DIRECTOR_APPOINTED: Nissim Darvish seat on Chemomab Therapeutics Ltd., effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-17T04:47:19.235235+00:00. event_id=alpha:event:transition:76els71ohondj - COMMITTEE_MEMBER_ADDED: Alan Moses member of Audit, effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-17T04:47:19.235235+00:00. event_id=alpha:event:transition:xze4lt8sz23j - COMMITTEE_CREATED: Audit · Chair; Nominating and Governance committee of Chemomab Therapeutics Ltd., effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-17T04:47:19.235235+00:00. event_id=alpha:event:transition:ioznmkvmehtu - COMMITTEE_MEMBER_ADDED: Joel Maryles member of Audit · Chair; Nominating and Governance, effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-17T04:47:19.235235+00:00. event_id=alpha:event:transition:1or8q6cxtja8m - COMMITTEE_CREATED: Compensation · Chair committee of Chemomab Therapeutics Ltd., effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-17T04:47:19.235235+00:00. event_id=alpha:event:transition:1rt8a8xnz4tln - COMMITTEE_MEMBER_ADDED: Nissim Darvish member of Compensation · Chair, effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-17T04:47:19.235235+00:00. event_id=alpha:event:transition:3lw0xgfaxvec - DIRECTOR_APPOINTED: Neil Cohen seat on Chemomab Therapeutics Ltd., effective 2020-01-01. Effective: 2020-01-01. Detected: 2026-10-17T04:47:19.235235+00:00. event_id=alpha:event:transition:1ib2lvpt7oxhv - COMMITTEE_CREATED: Compensation; Nominating and Governance · Chair committee of Chemomab Therapeutics Ltd., effective 2020-01-01. Effective: 2020-01-01. Detected: 2026-10-17T04:47:19.235235+00:00. event_id=alpha:event:transition:63gxv7h2v12v - COMMITTEE_MEMBER_ADDED: Neil Cohen member of Compensation; Nominating and Governance · Chair, effective 2020-01-01. Effective: 2020-01-01. Detected: 2026-10-17T04:47:19.235235+00:00. event_id=alpha:event:transition:i2ctikg3q6l2 ## Scoped resources - `alpha://company/chemomab-therapeutics-ltd` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record - `alpha://company/chemomab-therapeutics-ltd/identity` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=identity - `alpha://company/chemomab-therapeutics-ltd/corporate-structure` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=corporate-structure - `alpha://company/chemomab-therapeutics-ltd/board` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=board - `alpha://company/chemomab-therapeutics-ltd/committees` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=committees - `alpha://company/chemomab-therapeutics-ltd/leadership` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=leadership - `alpha://company/chemomab-therapeutics-ltd/ownership` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=ownership - `alpha://company/chemomab-therapeutics-ltd/financials` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=financials - `alpha://company/chemomab-therapeutics-ltd/capital-structure` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=capital-structure - `alpha://company/chemomab-therapeutics-ltd/compensation` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=compensation - `alpha://company/chemomab-therapeutics-ltd/governance` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=governance - `alpha://company/chemomab-therapeutics-ltd/shareholder-governance` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=shareholder-governance - `alpha://company/chemomab-therapeutics-ltd/audit` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=audit - `alpha://company/chemomab-therapeutics-ltd/legal` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=legal - `alpha://company/chemomab-therapeutics-ltd/risk` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=risk - `alpha://company/chemomab-therapeutics-ltd/cyber` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=cyber - `alpha://company/chemomab-therapeutics-ltd/ai-governance` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=ai-governance - `alpha://company/chemomab-therapeutics-ltd/agents` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=agents - `alpha://company/chemomab-therapeutics-ltd/ecosystem` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=ecosystem - `alpha://company/chemomab-therapeutics-ltd/events` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=events - `alpha://company/chemomab-therapeutics-ltd/relationships` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=relationships - `alpha://company/chemomab-therapeutics-ltd/assessments` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=assessments - `alpha://company/chemomab-therapeutics-ltd/evidence` (contract): https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record§ion=evidence ## Role modules - NOT_ASSERTED ## Attention - NO_RECORDS_FOUND ## Committee data - Claim alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_appointment:17: `{"kind":"committee_appointment","original_name":"Audit","category":"audit","role":"chair","person":{"alpha_id":"alpha:person:joel-maryles","name":"Joel Maryles"},"source_id":"board_seats"}` - Claim alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_appointment:18: `{"kind":"committee_appointment","original_name":"Audit","category":"audit","role":"member","person":{"alpha_id":"alpha:person:alan-moses","name":"Alan Moses"},"source_id":"board_seats"}` - Claim alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_appointment:19: `{"kind":"committee_appointment","original_name":"Audit","category":"audit","role":"member","person":{"alpha_id":"alpha:person:claude-nicaise","name":"Claude Nicaise"},"source_id":"board_seats"}` - Claim alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_appointment:21: `{"kind":"committee_appointment","original_name":"Compensation","category":"compensation","role":"chair","person":{"alpha_id":"alpha:person:nissim-darvish","name":"Nissim Darvish"},"source_id":"board_seats"}` - Claim alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_appointment:22: `{"kind":"committee_appointment","original_name":"Compensation","category":"compensation","role":"member","person":{"alpha_id":"alpha:person:neil-cohen","name":"Neil Cohen"},"source_id":"board_seats"}` - Claim alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_appointment:24: `{"kind":"committee_appointment","original_name":"Nominating and Governance","category":"nominating_governance","role":"chair","person":{"alpha_id":"alpha:person:neil-cohen","name":"Neil Cohen"},"source_id":"board_seats"}` - Claim alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_appointment:25: `{"kind":"committee_appointment","original_name":"Nominating and Governance","category":"nominating_governance","role":"member","person":{"alpha_id":"alpha:person:joel-maryles","name":"Joel Maryles"},"source_id":"board_seats"}` ## Leadership - Adi Mor: Director. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:5. Valid from: 2021-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6. - Alan Moses: Director, Audit. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:6. Valid from: 2021-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6. - Claude Nicaise: Director, Audit. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:7. Valid from: 2021-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6. - Dale Pfost: Director. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:8. Valid from: 2021-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6. - Joel Maryles: Director, Audit · Chair; Nominating and Governance. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:9. Valid from: 2021-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6. - Neil Cohen: Director, Compensation; Nominating and Governance · Chair. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:10. Valid from: 2020-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6. - Nissim Darvish: Director, Compensation · Chair. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:11. Valid from: 2021-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6. - Adi Mor: Director, Chief Scientific Officer. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:12. Valid from: 2023-03-20. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:0a6d88181566fb91facd65dc58b3461619162eb54f8c01be221d2b9aeabe7eaa. - Dale Pfost: Chairman of the Board, Chief Executive Officer. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:13. Valid from: 2023-03-20. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:d67e834750540b5de9e616c9c2a989cf3d671dd1f9b63af3421b8249e7bd9d74. - Donald Marvin: Chief Financial Officer, Executive Vice President and Chief Operating Officer. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:14. Valid from: 2023-03-20. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:30f078484ad42b7db98ae5d0f839c499b23a33b798561c25cfdc4096ba0547af. - Matthew Frankel: Chief Medical Officer. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:15. Valid from: 2023-03-20. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:12af43a6bb01e3773f017b270e7f79aeb9ab8eed80b489139819eab26a9dab3f. ## Roles - PUBLISHED ## Governance - NOT_ASSERTED ## Board committees - Audit: Chair Joel Maryles; Members Joel Maryles (Chair); Alan Moses; Claude Nicaise. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:16. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5. - Compensation: Chair Nissim Darvish; Members Nissim Darvish (Chair); Neil Cohen. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:20. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5. - Nominating and Governance: Chair Neil Cohen; Members Neil Cohen (Chair); Joel Maryles. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:23. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5. ## Financials - NOT_ASSERTED ## Workforce - NOT_ASSERTED ## Market and index context - PUBLISHED ## Legal Name - Chemomab Therapeutics Ltd.. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:legal_name:1. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:804db165675de611290ff8e6097e3c5d2d63f355a20d8417278fe230b3403f49. ## Entity Status - Public listing published. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:entity_status:3. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:804db165675de611290ff8e6097e3c5d2d63f355a20d8417278fe230b3403f49. ## Published Fact - US. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:published_fact:4. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:804db165675de611290ff8e6097e3c5d2d63f355a20d8417278fe230b3403f49. ## Committee Appointment - Joel Maryles: chair, Audit. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_appointment:17. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5. - Alan Moses: member, Audit. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_appointment:18. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5. - Claude Nicaise: member, Audit. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_appointment:19. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5. - Nissim Darvish: chair, Compensation. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_appointment:21. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5. - Neil Cohen: member, Compensation. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_appointment:22. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5. - Neil Cohen: chair, Nominating and Governance. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_appointment:24. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5. - Joel Maryles: member, Nominating and Governance. Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_appointment:25. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5. ## Security Listing - CMMB (NASDAQ). Claim: alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:security_listing:26. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:804db165675de611290ff8e6097e3c5d2d63f355a20d8417278fe230b3403f49. ## Coverage states | Field | Value | | --- | --- | | Identity | PUBLISHED | | Business | PUBLISHED | | Leadership | PUBLISHED | | Board and committees | PUBLISHED | | Governance | NOT_ASSERTED | | Financials | NOT_ASSERTED | | Workforce | NOT_ASSERTED | | Ownership | NOT_ASSERTED | | Ratings | NOT_PUBLISHED | | Market and index context | PUBLISHED | ## Public sources - alpha:projection-evidence:804db165675de611290ff8e6097e3c5d2d63f355a20d8417278fe230b3403f49: [Alpha canonical company public projection](https://www.alpha.ac/api/public/companies/chemomab-therapeutics-ltd). - alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6: [Chemomab Therapeutics Ltd. DEF 14A 2022-04-28](https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm). - alpha:projection-evidence:document:0a6d88181566fb91facd65dc58b3461619162eb54f8c01be221d2b9aeabe7eaa: [CMMB 10-K executive officers](https://www.sec.gov/Archives/edgar/data/1534248/000117891323001041/zk2329403.htm). - alpha:projection-evidence:document:d67e834750540b5de9e616c9c2a989cf3d671dd1f9b63af3421b8249e7bd9d74: [CMMB 10-K executive officers](https://www.sec.gov/Archives/edgar/data/1534248/000117891323001041/zk2329403.htm). - alpha:projection-evidence:document:30f078484ad42b7db98ae5d0f839c499b23a33b798561c25cfdc4096ba0547af: [CMMB 10-K executive officers](https://www.sec.gov/Archives/edgar/data/1534248/000117891323001041/zk2329403.htm). - alpha:projection-evidence:document:12af43a6bb01e3773f017b270e7f79aeb9ab8eed80b489139819eab26a9dab3f: [CMMB 10-K executive officers](https://www.sec.gov/Archives/edgar/data/1534248/000117891323001041/zk2329403.htm). - alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5: [Audit](https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm). ## Rights | Field | Value | | --- | --- | | public_retrieval | allowed | | agent_retrieval | allowed | | redistribution | not_granted | | model_training | not_granted | | commercial_use | not_specified | | relationship_pathfinding | not_granted | | direct_contact | not_granted | ## Limitations - Absence of a leadership role, committee, or disclosure is not evidence that it does not exist. - Only explicitly published canonical company identity and current confirmed public roles are included. - Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist. - Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights. - This Company Profile is an identity and evidence record, not an Alpha rating. ## Alternate representations - [Canonical profile](https://registry.alpha.ac/companies/chemomab-therapeutics-ltd) - [Public Markdown](https://registry.alpha.ac/companies/chemomab-therapeutics-ltd.md) - [Public JSON](https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record) - [JSON-LD](https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=jsonld) - MCP resource: `alpha://companies/chemomab-therapeutics-ltd` at https://mcp.alpha.ac/mcp ## Connected governance records Only explicitly published, rights-cleared records. Missing records do not establish absence, safety, or complete coverage. ## Critical-risk oversight Snapshot as of 2026-10-17T18:19:41.281654+00:00; recorded 2026-10-17T18:19:41.281654+00:00. Every published assignment for this snapshot is listed. Only explicitly reviewed, rights-cleared assignments in effect on the as-of date, in the company's own wording. An assignment shows where oversight is placed, not whether it is effective. Missing records do not establish absence.